Hereditary Fructose Intolerance: Aldolase B Deficiency Postprandial Hypoglycemia Hepatic Injury and Dietary Management
An autosomal recessive inborn error of fructose metabolism caused by biallelic loss-of-function mutations in ALDOB encoding aldolase B — clinically defined by acute postprandial hypoglycemia, vomiting, lactic acidosis, hyperuricemia, and acute hepatic injury triggered by fructose, sucrose, or sorbitol ingestion, with lifelong fructose-free diet as the disease-defining therapy and a profound aversion to sweet foods that is itself protective in many affected individuals.
S1. Pathophysiology and Aldolase B Biology
Hereditary fructose intolerance (HFI) — first described by Chambers and Pratt in 1956 — is an autosomal recessive inborn error of carbohydrate metabolism caused by biallelic loss-of-function mutations in the ALDOB gene encoding aldolase B (fructose-1,6-bisphosphate aldolase), one of three tissue-specific aldolase isoenzymes (aldolase A in muscle and red blood cells; aldolase C in brain). Aldolase B is expressed predominantly in liver, kidney, and intestinal mucosa where it catalyzes two reactions in fructose and glycolysis metabolism: the cleavage of fructose-1-phosphate to dihydroxyacetone phosphate and glyceraldehyde, and the reversible cleavage of fructose-1,6-bisphosphate in glycolysis.
The clinical consequences of aldolase B deficiency unfold immediately on fructose exposure and reflect both what accumulates upstream of the enzymatic block and what fails to be produced downstream:
- Accumulation of fructose-1-phosphate in hepatocytes traps inorganic phosphate, depleting cellular ATP and producing severe acute hepatic injury, lactic acidosis, hyperuricemia, and renal tubular dysfunction.
- Inhibition of gluconeogenesis from the upstream accumulation produces acute hypoglycemia within 30–90 minutes of fructose ingestion, particularly in fasted or carbohydrate-depleted patients.
- Inhibition of glycogenolysis from sequestration of phosphate compounds prevents glucose mobilization from hepatic glycogen, deepening the hypoglycemia.
- Renal tubular acidosis and proximal tubule dysfunction arise from a parallel mechanism in renal aldolase B-expressing tubular cells.
The acute clinical picture in an unrecognized infant given fruit, juice, or sucrose-containing formula is dramatic and life-threatening: vomiting, lethargy, profound hypoglycemia, lactic acidosis, hyperuricemia, hepatomegaly, and acute liver and renal failure. In contrast, older children and adults with established HFI usually develop a strong protective aversion to sweet foods early in life — fruits, sweets, sucrose-containing products taste unpleasant or are immediately followed by nausea and discomfort — and unintentionally restrict their own dietary fructose intake. This aversion is so consistent that “dental decay-free child or adult who refuses sweets” is a classic diagnostic clue.
The genetic spectrum is dominated by a small number of common founder mutations in Western populations. The p.A149P (A149P) variant accounts for approximately 70% of pathogenic alleles in Northern European populations, with smaller contributions from p.A174D, p.N334K, and others. Most patients are homozygous A149P or compound heterozygous A149P/other-variant. Different ethnic populations show different founder mutations. Targeted mutation analysis is therefore a practical first-line genetic test, with full ALDOB sequencing reserved for cases where targeted testing is negative.
S2. Diagnostic Criteria and Safe Workup
Diagnosis combines compatible clinical features (acute illness on fructose exposure, postprandial symptoms, sweet aversion, family history) with genetic confirmation by ALDOB targeted mutation analysis or full sequencing. The historical “fructose tolerance test” — IV fructose administration to provoke hypoglycemia — is now strictly contraindicated because it can be fatal in affected individuals.
| Investigation | Finding in HFI | Clinical role |
|---|---|---|
| ALDOB targeted mutation analysis (A149P + other common variants) | Pathogenic biallelic variants — most commonly A149P homozygous or compound heterozygous | First-line definitive diagnostic test |
| Full ALDOB gene sequencing | Pathogenic variants when targeted negative | Second-line confirmation |
| Liver function tests during acute episode | Elevated AST, ALT, prolonged PT, hypoglycemia, hyperammonemia in severe cases | Acute presentation assessment |
| Lactate, uric acid, magnesium, phosphate | Lactic acidosis, hyperuricemia, hypophosphatemia, hypomagnesemia during acute episode | Biochemical signature of acute attack |
| Glucose monitoring during acute episode | Hypoglycemia (often profound, <40 mg/dL) | Confirms hypoglycemic component |
| Urinalysis with tubular function panel | Proximal RTA, glycosuria, generalized aminoaciduria (Fanconi-like syndrome) during acute episode | Identifies renal tubular involvement |
| Liver biopsy with aldolase B activity assay | Reduced aldolase B activity; histology shows steatosis and glycogen depletion | Historical gold standard; rarely needed now |
| IV fructose tolerance test | Was historical diagnostic; produces severe acute illness | STRICTLY CONTRAINDICATED — fatal in affected patients |
| Fructose breath test | Not appropriate for HFI diagnosis; may produce severe symptoms | Contraindicated in suspected HFI |
| Family history (3-generation pedigree) | Autosomal recessive pattern, consanguinity | Supports diagnosis; identifies at-risk siblings |
| Dental examination | Strikingly absent dental caries even in adults (sweet avoidance) | Classic supportive feature |
| Detailed dietary history | Lifelong aversion to fruits, sweets, sucrose; symptomatic response to fructose-containing foods | Important clinical clue |
The shift to genetic confirmation rather than provocation testing represents the most important diagnostic safety advance of the past two decades. Suspected HFI in any patient — child or adult presenting with characteristic features, family member of an affected individual, incidental finding of A149P heterozygosity on broader genetic testing — should proceed directly to ALDOB targeted mutation analysis rather than functional or provocation testing. Hospital protocols and laboratory request forms should specifically include HFI in the differential to ensure that targeted testing is offered.
S3. Treatment Strategy and Lifelong Dietary Management
Treatment is dietary — strict lifelong elimination of fructose, sucrose, and sorbitol from food, beverages, and medications. The disease has no pharmacologic disease-modifying therapy; the metabolic block cannot be bypassed because aldolase B is essential for fructose metabolism.
Compliance is generally excellent because the protective sweet aversion makes adherence intuitive for most affected individuals — they find fructose-containing foods unpleasant or symptom-provoking.Forbidden sugars
- Fructose — fruits (all), fruit juices, honey, agave syrup, fruit-flavored products, high-fructose corn syrup beverages, dried fruits.
- Sucrose — ordinary table sugar (a disaccharide of glucose + fructose, hydrolyzed to fructose during digestion), virtually all “sweetened” commercial products, baked goods, candies, soft drinks, breakfast cereals with added sugar, condiments and sauces containing sugar.
- Sorbitol — sugar-free gum and candy (sorbitol is metabolized to fructose by sorbitol dehydrogenase), some medications and infant formulas using sorbitol as sweetener or stabilizer.
- Hidden fructose — many medications use sucrose, sorbitol, or fructose as binding agents, fillers, or sweeteners; some vaccines and parenteral nutrition formulations contain sucrose or sorbitol. Pharmacist review of all medications is essential.
Safe carbohydrates
Glucose, lactose (milk sugar), maltose, and starch are safe and provide all needed dietary carbohydrate. Safe foods include meats, fish, eggs, dairy products (milk, cheese, yogurt without added sugar), grains (rice, pasta, bread without added sugar or fruit), most vegetables (with caution about a few sweeter vegetables like carrots, peas, beetroot in large quantities), and glucose-based snacks and beverages.
Nutritional adjuncts
Because fruits are eliminated, vitamin C supplementation at approximately 100 mg/day is appropriate. Folate supplementation may also be needed because some folate-rich foods are co-eliminated. Multivitamin supplementation should be fructose-free and screened with a dietitian. Multivitamins specifically formulated for HFI exist.
Medication and parenteral management
Every prescription, over-the-counter, and supplement formulation should be reviewed for fructose, sucrose, or sorbitol content. Liquid pediatric formulations are particularly likely to contain sucrose or sorbitol. IV fluids must be fructose-free — glucose-based (D5W, D10W) or saline. Anesthesia and surgical fluid orders must be explicitly fructose-free. Patient identification (MedicAlert bracelet, wallet card, electronic medical record allergy field) is essential.
Pediatric management and weaning
For children with confirmed HFI, structured weaning with fructose-free solid foods is essential. Lactose-containing infant formula is appropriate; sucrose-containing or fruit-juice-flavored formulas are contraindicated. Pediatric dietitian involvement is recommended throughout childhood to ensure adequate nutrition with strict avoidance.
| Approach | Best evidence niche | Practical positioning |
|---|---|---|
| Lifelong fructose/sucrose/sorbitol-free diet | Primary therapy | Disease-defining; no pharmacologic alternative |
| Pediatric dietitian involvement | Childhood weaning + growth | From diagnosis through adolescence |
| Adult dietitian periodic review | Ongoing adherence + nutritional adequacy | Annual or biennial |
| Vitamin C supplementation | Fruit-elimination consequence | ~100 mg/day; fructose-free formulation |
| Folate supplementation | If dietary folate suboptimal | Selected supplementation |
| Medication audit for fructose/sucrose/sorbitol | Continuous lifelong responsibility | Pharmacist + clinician review |
| Glucose-only IV fluids | Acute and perioperative care | Mandatory — explicitly ordered |
| Medical alert ID + emergency card | Unconscious or non-communicative emergencies | Essential for adult patients |
| Acute attack management (glucose, supportive) | Inadvertent exposure | IV glucose to correct hypoglycemia + supportive care |
| Genetic counseling | Family planning; sibling screening | At diagnosis and reproductive ages |
| Pre-pregnancy and pregnancy management | Fetal nutrition in affected mothers | Multidisciplinary metabolic and obstetric input |
S4. Monitoring and Long-Term Outcomes
Surveillance focuses on adherence assessment, nutritional adequacy, hepatic and renal monitoring, and identification of inadvertent fructose exposures.
| Domain | Recommended interval | Trigger for intervention |
|---|---|---|
| Dietary adherence review with dietitian | Annually (children); biennially (adults) | Identified gaps → counseling and reinforcement |
| Liver function tests (AST, ALT, GGT) | Annually | Persistent elevation → review for hidden fructose |
| Renal function (creatinine, urinalysis) | Annually | Tubular dysfunction → review for exposures |
| Lipid panel, uric acid | Annually in adults | Standard cardiovascular surveillance |
| Growth assessment (pediatric) | Each pediatric visit | Failure to thrive → dietary intensification |
| Vitamin status (C, folate, broader if indicated) | Annually or as indicated | Deficiency → supplement adjustment |
| Medication audit at each visit | Every prescription change | New fructose-containing agent → substitute |
| Emergency identification update | Annually + with address/medical changes | Lost or outdated → replace |
| Family screening for siblings | At diagnosis | Identification of affected siblings → enroll in care |
| Genetic counseling at reproductive ages | As appropriate | Family planning support |
| Hepatic ultrasound | Periodic adult assessment | Detects steatosis or unexpected hepatic changes |
Long-term outcomes with strict dietary adherence are excellent. Most affected individuals achieve normal growth, normal life expectancy, and minimal disease-related morbidity. The protective sweet aversion that develops early in life supports adherence, and the absence of dental caries that this aversion produces is itself a recognized supportive feature. Inadvertent fructose exposures from hidden sources in medications or unrecognized food ingredients can produce acute attacks at any age, making continued vigilance lifelong rather than a phase of childhood management.
S5. Clinical Commentary and Referral Triggers
The most clinically consequential reframe in hereditary fructose intolerance over the past three decades has been the shift from functional and provocation diagnostic testing — which carried fatal risk in affected patients — to safe genetic confirmation through ALDOB targeted mutation analysis. Any suspected HFI in any patient should proceed directly to genetic testing rather than IV fructose tolerance test, fructose breath test, or empirical dietary challenge, all of which can produce severe or fatal acute illness in confirmed disease.
The second clinical reframe is the recognition that adult presentations of HFI exist — patients who self-managed through lifelong sweet aversion and never received formal diagnosis, often identified incidentally through genetic testing for other indications, family screening after a child is diagnosed, or unexpected acute illness from a fructose-containing IV fluid or medication. Adult presentations highlight the importance of identifying the diagnosis even in apparently healthy individuals because of the perioperative and acute care implications.
- Newly suspected or confirmed HFI — for comprehensive workup and family counseling
- Pediatric weaning planning with fructose-free dietary instruction
- Acute presentation with inadvertent fructose exposure
- Pre-anesthesia or pre-operative planning in known HFI patient
- Family screening of siblings or extended family
- Pregnancy management in affected mother
- Unexplained adult hepatomegaly, hypoglycemia, or tubular dysfunction with possible occult HFI
- Medication review for fructose/sucrose/sorbitol content in complex regimens
Practice Insights — Synthesized Patterns for Hereditary Fructose Intolerance Care
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.) Across published HFI case series and metabolic clinic experience, the disease’s two most consistent pitfalls are the use of contraindicated fructose-containing IV fluids in unrecognized adult HFI patients during perioperative or acute care — producing severe iatrogenic injury — and the unnecessary distress of incomplete medication review when patients are prescribed liquid formulations containing sorbitol or sucrose without recognition of the HFI implication. Experienced practice has reframed HFI as primarily a “lifelong vigilance against hidden fructose in IV fluids and medications” disease, with the dietary management generally well-handled by the protective sweet aversion.
What the Guidelines Underweight
Experienced metabolic clinicians have learned that medication-related fructose exposure is the most common source of inadvertent acute attacks in adolescents and adults, not dietary indiscretion. Liquid pediatric formulations, some adult medications using sorbitol as a sweetener, and rare parenteral formulations containing sucrose or fructose all pose risks that dietary education alone does not address. A structured medication audit at every clinical encounter, with the pharmacist explicitly informed of the HFI diagnosis, is established practice.
Patterns That Repeat Across Series
The recurring iatrogenic injury pattern in published case series is an adult HFI patient — sometimes previously undiagnosed and managing the disease through sweet aversion alone — admitted for surgical or medical care, receiving IV fructose-containing fluids (rare in modern practice but still encountered in older formulations and some international settings), and developing acute hepatic and renal failure within hours. Experienced practice has prioritized medical alert identification and explicit “no fructose” markers in electronic medical records to reduce this risk.
Bedside Heuristic
The established three-question heuristic for any unexplained acute hypoglycemia with vomiting and hepatic injury in a child after a meal is: (a) was there fruit, fruit juice, sweet food, or sucrose-containing food in the preceding 30–90 minutes, (b) is there family history of recurrent unexplained childhood illness or selective sweet aversion, and (c) is there absent dental caries despite age. Affirmative answers should trigger immediate ALDOB targeted mutation analysis and complete fructose avoidance pending results.
Illustrative Scenario — Adult HFI Recognized at Pre-Operative Assessment
(Composite teaching scenario assembled from published patterns; not an individual patient.)An illustrative scenario from the literature describes a young adult presenting for elective surgery with a lifelong history of “strong dislike of fruits and sweets” that the patient and family had never recognized as medically significant. Pre-operative dietary screening prompted the anesthesiologist to ask specifically about post-prandial symptoms after sweet foods, which revealed lifelong nausea after any fruit ingestion. Targeted ALDOB mutation analysis was obtained and returned homozygous for A149P, establishing HFI diagnosis. Surgical fluids were modified to glucose-saline only, peri-operative medications were audited for sorbitol or sucrose content, and post-operative recovery was uneventful. The patient was enrolled in metabolic clinic follow-up and provided with medical alert identification.
What this scenario teaches: any patient describing lifelong selective sweet aversion combined with post-sweet symptom history warrants ALDOB targeted mutation analysis, and pre-anesthesia screening should explicitly inquire about sweet aversion and post-prandial symptoms — the diagnosis materially changes peri-operative fluid and medication choices.
- Genetic testing rather than provocation testing. Established practice obtains ALDOB targeted mutation analysis as first-line diagnostic test for suspected HFI, with full sequencing reserved for negative targeted testing. The historical IV fructose tolerance test is strictly contraindicated because of fatal risk in affected patients.
- Structured medication audit at every visit. Refined practice reviews every prescription, OTC product, and supplement for fructose, sucrose, or sorbitol content at every clinical encounter, with pharmacist involvement when complex regimens are present — medication-related exposures account for most inadvertent acute attacks in adolescents and adults.
- Medical alert identification mandatory. Experienced practice considers medical alert bracelet or equivalent identification essential for adult HFI patients because peri-operative and acute care fluid orders can include fructose-containing solutions if the diagnosis is not communicated when the patient is unable to advocate.
- Pre-anesthesia explicit “no fructose” order. Refined practice ensures that pre-operative and intra-operative orders explicitly specify fructose-free fluids (D5W, D10W, normal saline) and that anesthesia team is informed of the diagnosis at the pre-anesthesia visit, not on the day of surgery.
S7. Frequently Asked Questions
- Hereditary Hemochromatosis: Diagnosis and Management
- Drug-Induced Liver Injury: ACG and EASL Diagnosis with R-Ratio Hy’s Law RUCAM Causality and N-Acetylcysteine Management
- Lower GI Bleed Admission Order Set: Resuscitation, Colonoscopy Timing, and Management
- Toxic Megacolon: Jalan Criteria Surgical Indication ACG Medical Rescue and ICU Management
- Acetaminophen Hepatotoxicity: Rumack-Matthew Nomogram, N-Acetylcysteine Protocols, and Liver Transplant Criteria
- Chronic Pancreatitis: Etiology, Imaging Diagnosis, Pain Management, and Pancreatic Insufficiency